160 HEALTH (02656) saw its shares decline by more than 30%, following a sharp rally of 115% over the previous seven trading sessions. The stock had risen as much as 11-fold since its listing just six months ago. As of the latest update, the stock was down 30.4%, trading at HK$105.7, with a turnover of HK$179 million.

On March 11, the company announced that, through its integrated model of "platform + AI agents + operations," it is gradually deploying a "digital medical staff" system for healthcare institutions, promoting the application of AI agents like OpenClaw in medical scenarios. Subsequently, the company disclosed positive progress in its digital healthcare solutions business as of December 31, 2025. During the 2025 fiscal year, the group entered into operational partnerships with 82 public secondary甲 and above hospitals for its "160AI Hospital" initiative, representing a year-on-year increase of over 720%. In the fourth quarter of 2025 alone, 52 new public hospital partnerships were added, achieving a quarter-on-quarter growth of 420%.

Additionally, while 160 HEALTH was initially set to face its first lock-up expiration on March 16, the company announced on March 13 that shareholders had voluntarily extended the lock-up period to September 16. On March 17, the company issued a profit alert, forecasting an adjusted net profit between RMB 3 million and RMB 5 million for the 2025 fiscal year, compared to an adjusted net loss of RMB 31.5 million in the same period last year. This marks the group’s first full-year profit on an adjusted basis.